
NervGen Pharma fell 69.5% from $5.97 to $1.82, behind the S&P 500's +7.3%. Its worst day was May 22 (−43.5%), and its low came Nov 3 at $1.32.
Jan 8, 2026 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
NervGen Pharma shares rose 15.6%, while the S&P 500 rose 0.8%.
+15.6% · S&P 500 +0.8%
The offering is being made pursuant to a prospectus supplement to an amended and restated short form base shelf prospectus dated December 15, 2025 (the "Base Shelf Prospectus") filed in all of the provinces and
Story events cover the past 12 months · Times ET
−43.5%, the year's worst day, on 12M shares, the year's heaviest volume · S&P 500 +0.4%
EPS of $-0.27 was reported on $0.00 revenue.
0.0% · S&P 500 +0.7%
NervGen Pharma closed at its lowest level of the year, 77.9% below where the year started.
−2.2% · S&P 500 +0.3%
EPS of $-0.04 missed the $0.01 estimate on $0.00 revenue.
−3.2% · S&P 500 −1.9%
Where it ended: a close of $1.82 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 14, 2027 (EPS est. $-0.10).
Nothing in the past 12 months.
All NGEN dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NGEN and SPY from Benzinga historical bars. Not investment advice.